LECANEMAB and DONANEMAB COMBINED TREATMENT
ABOUT LECANEMAB & DONANEMAB COMBINED TREATMENT
Lecanemab & Donanemab are approved to treat adults in the early stages of Alzheimer’s disease who have one or no copies of the apolipoprotein E4 gene (ApoE4). A person can have no copies, one copy or two of this gene. Approximately 15% of those diagnosed with Alzheimer’s disease have two copies of this gene, known as homozygous patients, and are at increased risk of developing Alzheimer’s disease, while people with one copy also have an increased risk.
IMPORTANT INFORMATION
Treatment will be undergoing and completed by your local hospital or private local hospital under the doctors and staff from that particular hospital and under additional supervision of doctors directed by the US manufacturer.
LEGAL DISCLAIMER
We are strictly recommending 2-3 years if not 5 years treatment. If in meantime the manufacturer finds another breakthrough version of improved medication the treatment will be carried out with that new medications. Additional charges might applies.
PACKAGING & LOGISTIC DATA
All medication will be delivered directly to your Hospital or private hospital only.
| L 0 x W 0 x H 0cm | Units / Case | Case's / Layer | Layers / Pallet | Case's / Pallet | Pallet Height |
 |
 |
 |
 |
 |
|
| Total: | 0 | 0 | 0 | 0 | >0cm |
| Full lorry: 34 Pallets |
 |
Full Jumbo lorry: 60-66 Pallets |
Container 20" 11-12 Pallets |
Container 40" 22-24 Pallets |
|
| |
